文献速递关节外科

全膝关节置换术中应用收肌管导管是否有益?一项随机临床试验

Is There Benefit in Using an Adductor Canal Catheter in Knee Arthroplasty? A Randomized Clinical Trial.
PubMed 文献 · J Arthroplasty · 2025-06-04

该随机、开放标签、非劣效性试验纳入126例择期初次单侧全膝关节置换术患者,比较术前放置收肌管导管与不放置对术后第2天疼痛评分的影响。结果显示不放置收肌管导管非劣效于放置,主要结局平均差异1.06分(95%CI 0.18至1.94),15天内阿片类药物用量、住院时长及再就诊频率无显著差异。

要点

  • 不放置收肌管导管在术后第2天疼痛评分上非劣效于放置(平均差异1.06分,95%CI 0.18至1.94)。
  • 15天总阿片类药物片剂消耗量:收肌管导管组46.0片 vs 不放置组41.9片,P=0.55,无显著差异。
  • 住院时长和再就诊频率无显著差异,收肌管导管的增量获益小,可能不足以支持常规使用。

核心结论

  • 不放置收肌管导管非劣效于放置收肌管导管,提示收肌管导管的增量获益小,可能不足以支持其常规使用。
  • 需要进一步试验明确这一昂贵技术的适当用途;在获得此类证据前,收肌管导管对大多数患者的价值仍存疑。

研究设计与样本

  • 随机、开放标签、非劣效性试验,在一家医疗中心的骨科实践中纳入择期初次单侧全膝关节置换术患者。
  • 所有参与者接受术中长效麻醉药关节周围注射,并按1:1随机分为术前放置收肌管导管组(标准治疗对照)和不放置收肌管导管组(干预组)。
  • 共126例患者被随机分组。

主要发现

  • 主要结局(术后第2天患者报告的0至10数字评定量表疼痛评分)平均差异为1.06分,95%CI为0.18至1.94;因上限未跨越预设非劣效界值,非劣效性成立。
  • 术后15天平均总阿片类药物片剂消耗量:收肌管导管组46.0片 vs 不放置组41.9片,P=0.55,无显著差异。
  • 住院时长和再就诊频率无显著差异。

关键数值与推荐

  • 主要结局非劣效性界值:原文未报告具体数值,仅说明95%CI上限0.18至1.94未跨越预设非劣效界值。
  • 术后15天阿片类药物消耗量:收肌管导管组46.0片 vs 不放置组41.9片,P=0.55。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adductor canal catheters (ACCs) are widely used for adjunctive pain control for patients undergoing total knee arthroplasty (TKA), but no fully powered clinical trial of the device has been reported despite the device's cost and potential adverse effects. We conducted a randomized, open-label, non-inferiority trial to assess whether not implanting the ACC was noninferior to implanting an ACC on second-postoperative-day pain levels among patients undergoing elective primary TKA. METHODS: Patients undergoing elective primary unilateral TKA in an orthopaedic practice in one medical center were eligible. All participants received intraoperative periarticular injections of long-acting anesthetics and were randomized 1:1 to have an ACC placed preoperatively (standard-of-care control condition) or not have an ACC placed (intervention arm). The primary outcome was the patient-reported 0 to 10 numerical rating scale for pain on the second postoperative day. Secondary outcomes included pain scores and medication use over the 15-day postoperative period, hospital length of stay, and return to care. In all, 126 patients were randomized. RESULTS: The mean difference in the primary outcome was 1.06 points with a 95% confidence interval of 0.18 to 1.94; since the upper bound did not cross the predetermined noninferiority margin, noninferiority was confirmed. There was no significant difference in mean total opioid tablets consumed over the 15-day postoperative period (46.0 tablets (ACC group) versus 41.9 tablets (non-ACC group), P = 0.55). There were no significant differences in hospital length of stay or frequency of return to care. CONCLUSIONS: We found that not using the ACC was noninferior to using the ACC, suggesting that the incremental benefit of the ACC is small and likely of insufficient magnitude to justify its routine use for patients undergoing TKA. Further trials will be helpful in defining the appropriate use of this costly technology; until such evidence becomes available, the value of the ACC for most patients remains in doubt.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Hinman AD, Lee DJ, Cortese KD, et al. Is There Benefit in Using an Adductor Canal Catheter in Knee Arthroplasty? A Randomized Clinical Trial. J Arthroplasty. 2025. PMID: 40480328. doi:10.1016/j.arth.2025.05.109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。